CLINICAL
The drug, a Nav1.8 inhibitor, is the first new mechanism approved for acute pain in two decades.
The Food and Drug Administration on Thursday cleared suzetrigine, a first-in-class Nav1.8 inhibitor, for the treatment of moderate-to-severe acute post-surgical pain in adults — the first time a non-opioid mechanism has been approved for this indication in more than 20 years.
The agency cited two pivotal trials in patients recovering from abdominoplasty and bunionectomy, in which suzetrigine outperformed placebo on the standard 48-hour pain index.
More from the wire
CLINICAL
A two-year study finds that simplifying the order set, not adding alerts, drove the change.
CLINICAL
An internal evaluation found visit notes shrunk by 38% with no measurable change in clinical accuracy.
CLINICAL
A reworked insertion bundle and a no-blame dashboard cut CLABSI by 41%, the system reports.
The Morning Round
A free daily email for clinicians, distilled at 6 a.m. ET. One short note. Unsubscribe in one click.
Comments
Be the first to comment.
Thanks — your comment is in the queue. An editor reviews comments before they appear. If yours is on point, you'll see it here within a few hours.